Richardson, Paul G.
Lee, Hans C.
Abdallah, Al-Ola
Cohen, Adam D. http://orcid.org/0000-0003-0939-3843
Kapoor, Prashant
Voorhees, Peter M.
Hoos, Axel
Wang, Karrie
Baron, January
Piontek, Trisha
Byrne, Julie
Richmond, Scott
Jewell, Roxanne C.
Opalinska, Joanna
Gupta, Ira
Lonial, Sagar http://orcid.org/0000-0002-8322-9323
Funding for this research was provided by:
GlaxoSmithKline
Article History
Received: 3 April 2020
Revised: 11 August 2020
Accepted: 23 September 2020
First Online: 23 October 2020
Conflict of interest
: P.G.R. has received grant funding and personal fees from Celgene, Takeda, and Oncopeptides, and personal fees from Janssen, Karyopharm and Sanofi. H.C.L. has received grant funding and personal fees from Amgen, Celgene, Janssen, and Takeda; personal fees from GSK and Sanofi, and grant funding from Daiichi Sankyo. A.-O.A. declares no conflict of interest. A.D.C. has received grant funding from GSK, BMS, and Novartis; personal fees from Janssen, Takeda, Oncopeptides, Kite Pharma and Seattle Genetics, and personal fees and other association with GSK and Celgene. P.K. has received grant funding from GSK, Amgen, Sanofi, Takeda, Sorrento and Janssen (to the institution) and served on an advisory board for GSK (for which the institution received an honorarium). P.M.V. has received personal fees from Adaptive Biotechnologies, BMS/Celgene, Janssen, Novartis, Oncopeptides and TeneoBio. A.H., J. Baron, T.P. and J.O. are employees of and hold stocks and shares in GSK. K.W. and S.R. are employees of GSK. J. Byrne is an employee of GSK and holds stocks/shares in GSK, Adaptimmune, and Novartis. I.G. and R.C.J. are employees of GSK and hold stocks/shares in GSK and Novartis. S.L. has received grant funding and personal fees from Celgene and Takeda, and personal fees from Novartis, BMS, GSK, Amgen, Merck and Janssen.